These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 33387667)

  • 1. Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease.
    Kirchgesner J; Desai RJ; Beaugerie L; Schneeweiss S; Kim SC
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):314-324.e16. PubMed ID: 33387667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases.
    Singh S; Heien HC; Herrin J; Dulai PS; Sangaralingham L; Shah ND; Sandborn WJ
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):e74-e88. PubMed ID: 33640480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Vedolizumab Versus Tumor Necrosis Factor α Antagonists in an Elderly IBD Population: A Single Institution Retrospective Experience.
    Pabla BS; Alex Wiles C; Slaughter JC; Scoville EA; Dalal RL; Beaulieu DB; Schwartz DA; Horst SN
    Dig Dis Sci; 2022 Jul; 67(7):3129-3137. PubMed ID: 34268660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.
    Rundquist S; Sachs MC; Eriksson C; Olén O; Montgomery S; Halfvarson J;
    Aliment Pharmacol Ther; 2021 Feb; 53(4):471-483. PubMed ID: 33340426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-Tumor Necrosis Factor Agents in Older Adults.
    Kochar B; Pate V; Kappelman MD; Long MD; Ananthakrishnan AN; Chan AT; Sandler RS
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1299-1305.e5. PubMed ID: 34481954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.
    Singh N; Rabizadeh S; Jossen J; Pittman N; Check M; Hashemi G; Phan BL; Hyams JS; Dubinsky MC
    Inflamm Bowel Dis; 2016 Sep; 22(9):2121-6. PubMed ID: 27542130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort Study.
    Singh S; Kim J; Luo J; Paul P; Rudrapatna V; Park S; Zheng K; Syal G; Ha C; Fleshner P; McGovern D; Sauk JS; Limketkai B; Dulai PS; Boland BS; Eisenstein S; Ramamoorthy S; Melmed G; Mahadevan U; Sandborn WJ; Ohno-Machado L
    Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2359-2369.e5. PubMed ID: 36343846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases.
    Singh S; Iversen AT; Allin KH; Jess T
    JAMA Netw Open; 2022 Sep; 5(9):e2234200. PubMed ID: 36178685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study.
    Pugliese D; Privitera G; Crispino F; Mezzina N; Castiglione F; Fiorino G; Laterza L; Viola A; Bertani L; Caprioli F; Cappello M; Barberio B; Ricci C; Balestrieri P; Daperno M; Pluchino D; Rizzello F; Scribano ML; Sablich R; Pastorelli L; Manguso F; Variola A; Di Sario A; Grossi L; Armuzzi A;
    Aliment Pharmacol Ther; 2022 Jul; 56(1):95-109. PubMed ID: 35876062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vedolizumab or Tumor Necrosis Factor Antagonist Use and Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease With Prior Malignancy: A Retrospective Cohort Study.
    Vedamurthy A; Gangasani N; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):88-95. PubMed ID: 33065312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic Review and Meta-Analysis: Preoperative Vedolizumab and Postoperative Complications in Patients with IBD.
    Moosvi Z; Duong JT; Bechtold ML; Nguyen DL
    South Med J; 2021 Feb; 114(2):98-105. PubMed ID: 33537791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
    Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
    Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients with Inflammatory Bowel Diseases.
    Singh S; Heien HC; Sangaralingham L; Shah ND; Sandborn WJ
    Dig Dis Sci; 2022 Jun; 67(6):2510-2516. PubMed ID: 34085174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
    Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
    United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis.
    Lukin D; Faleck D; Xu R; Zhang Y; Weiss A; Aniwan S; Kadire S; Tran G; Rahal M; Winters A; Chablaney S; Koliani-Pace JL; Meserve J; Campbell JP; Kochhar G; Bohm M; Varma S; Fischer M; Boland B; Singh S; Hirten R; Ungaro R; Lasch K; Shmidt E; Jairath V; Hudesman D; Chang S; Swaminath A; Shen B; Kane S; Loftus EV; Sands BE; Colombel JF; Siegel CA; Sandborn WJ; Dulai PS
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):126-135. PubMed ID: 33039584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
    Solitano V; Facciorusso A; Jess T; Ma C; Hassan C; Repici A; Jairath V; Armuzzi A; Singh S
    Clin Gastroenterol Hepatol; 2023 Apr; 21(4):907-921.e2. PubMed ID: 35944832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease.
    Innocenti T; Roselli J; Lynch EN; Apolito P; Parisio L; Bagnoli S; Macrì G; Rogai F; Tarocchi M; Milani S; Galli A; Milla M; Dragoni G
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e574-e579. PubMed ID: 35048649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
    Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
    J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Guardiola J; Jahnsen J; Lees C; Louis E; Lukáš M; Reinisch W; Roblin X; Jang M; Byun HG; Kim DH; Lee SJ; Atreya R
    BMC Gastroenterol; 2022 Jun; 22(1):291. PubMed ID: 35676620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-Line Biologic Therapy Following Tumor Necrosis Factor Antagonist Failure: A Real-World Propensity Score-Weighted Analysis.
    Ibing S; Cho JH; Böttinger EP; Ungaro RC
    Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2629-2638. PubMed ID: 36787837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.